The Argentine Senate will debate the new regulatory initiative aimed at establishing a robust medical cannabis and industrial hemp framework. The new regulatory project seeks to promote a law that will enable and encourage public, private, or mixed investment projects in the different segments of the medical cannabis and industrial hemp sectors. The debate will be held on Wednesday at 3 pm.
The Argentine Senate will begin to debate the national government’s project that establishes a regulatory framework for the development of a medical cannabis and industrial hemp industry. The meeting will be held on Wednesday at 3 pm, within the framework of a plenary session of the Agriculture, Livestock, and Fishing; Budget and Finance; Internal Security and Drug Trafficking Commissions.
The Minister of Productive Development, Matías Kulfas, will participate in the medical cannabis debate remotely, since the initiative was worked on for months in that ministry. The text was presented last June 1 at the Bicentennial Museum within the framework of the Economic and Social Council.
Medical Cannabis Bill to Complement Existing Legislation
The project comes to complement the current legislation (Law 27.350) that allowed an advance in the production of medical cannabis, but on a very low scale because it was limited exclusively to experimental purposes.
The government’s proposal, which will be discussed in commissions, aims at legalizing the production and development of the medical cannabis and industrial hemp production chain with a productive vision, subject to certain regulations, based on UN recommendations and studies carried out on pioneer countries at the global and regional level.
New Law Aimed at Establishing Framework for Industry
In Argentina, there are already medical cannabis related initiatives throughout the country (22 provincial and 80 municipal). According to the fine print of the bill, the intention is to establish a legal framework that authorizes -through a strong regulatory scheme- the stages of sowing, cultivation, harvesting, production, storage, transport, commercialization, import, export, and possession of cannabis seeds, the cannabis plant, and its derivatives.
It seeks to promote a law that enables and encourages public, private, or mixed investment projects in the different segments of the medical cannabis sectorial chain. It also includes the legalization of the different productive and commercialization links of hemp or industrial hemp and its by-products, which is a specific variety with low THC concentration (it is not psychoactive). The objective is to promote its use as an input for several productive sectors: textile fibers, clothing and footwear, cosmetics, construction materials, paper.
According to the government’s rationale, it is important to legalize medical cannabis production, excluding it from the list of narcotic drugs (it was included in 1977). Hemp is included in the law because it is necessary to regulate and control the activity to prevent illegal crops of psychoactive cannabis from being hidden in hemp fields.
Creation of a Hemp and Medical Cannabis Regulatory Body
Likewise, the creation of a regulatory agency is contemplated, which will act as the governing and articulating body of the cannabis production chain and will be in charge of the multiple regulatory bodies involved. The Regulatory Agency of the Hemp and Medical Cannabis Industry (ARICCAME) will have technical, functional, and financial autonomy. It will orbit within the Ministry of Productive Development and will have jurisdiction throughout the national territory.
Among its functions will be to regulate the operation of the medical cannabis and industrial hemp chain, oversee compliance with the provisions issued for this purpose and coordinate the necessary actions with the rest of the competent public authorities.
Its board of directors will be made up of representatives of the public sector with the rank and hierarchy of secretary. And it will be the official appointed by the portfolio headed by Kulfas, who will be the president.
The medical cannabis and industrial hemp initiative contemplates a sanctioning regime for non-compliance with the provisions and/or regulations issued as a consequence thereof, with sanctions ranging from a warning to disqualification to operate within the terms provided for, including fines, suspension, and revocation of the authorization.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Tiempo Argentino, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.